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Abstract 
BACKGROUND: Gastric motility is a key-factor in the pathogenesis of functional dyspepsia (FD). 
13C-octanoic acid breath test (OBT) is a tool used for measuring gastric emptying time in clinical 
setting. We aimed to investigate the variation in FD symptoms and OBT parameters before and after 
treatment with buspirone, amitriptyline or clebopride. 
METHODS: Between Jan-2007 and Dec-2014, we enrolled 59 patients with FD unresponsive to first-
line therapy with proton pump inhibitors and/or domperidone that underwent OBT before and after 3 
months of buspirone (n=32), amitriptyline (n=16) or clebopride (n=11) treatment.   
RESULTS: Early satiation severity was positively correlated with gastric half emptying time (t1/2) 
(r=0.3789, p=0.003) and gastric lag phase (r=0.3371, p=0.011), and negatively correlated with gastric 
emptying coefficient (r=-0.3231, p=0.015). A reduction in t1/2 measurement in association to post-
prandial fullness, and early satiation severity improvement was observed (p=0.009, p=0.005 and 
p<0.001, respectively). Patients treated with buspirone obtained both a decrease in t1/2 (p=0.005) and an 
amelioration in early satiation (p=0.001). Patients under amitriptyline treatment experienced an 
improvement in post-prandial fullness (p=0.046), whereas no variation was reported in patients treated 
with clebopride. 
CONCLUSIONS: Patients with FD, non-responders to first-line therapy and reporting meal-related 
discomfort, may benefit from buspirone or amitriptyline-based therapies. 
 
Key words: Breath test - Functional dyspepsia - Gastrointestinal motility 
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Dyspepsia is a common disorder characterized by upper abdominal discomfort or pain and 
meal-related symptoms, with a notable impact on quality of life and sense of well-being of affected 
subjects.1 In the clinical context, a key issue is the accurate identification of patients with dyspepsia 
who require further investigation to rule out serious underlying structural diseases.2 Despite a certain 
degree of overlapping features, according to Rome IV criteria, functional dyspepsia (FD) is defined as 
the predominant presence of one or more symptoms including bothersome postprandial fullness or 
early satiation (post-prandial distress syndrome), epigastric pain (epigastric pain syndrome) or 
epigastric burning, occurring for the last 3 months with the onset occurring at least 6 months prior to 
diagnosis, in absence of evident structural disease.3, 4 While the global prevalence of FD is estimated to 
be 10-30% worldwide,3 in Italy, in the general population, it reaches to 11% with unemployment, 
divorce and smoking, but not  Helicobacter pylori (H. pylori) infection, being the main cause 
associated with an increased risk.5  
The pathogenesis of FD is likely multifactorial and still unclear; however, impaired 
gastrointestinal motility with delayed gastric emptying, impaired gastric accommodation after ingestion 
of a meal, and gastric and duodenal hypersensitivity to distension and intraluminal contents, seem to 
play a role in a substantial group of patients.6 Although the gold standard for the diagnosis of delayed 
gastric emptying is gastric scintigraphy,7, 8 this method has some limitations mainly due to the use of 
radioactive material. As a consequence, it cannot be performed in pregnant women and may raise some 
safety concerns in breast-feeding women and young patients. Furthermore, scintigraphy is a relatively 
expensive procedure not always available outside specialist centers. Therefore, 13C-octanoic acid breath 
test (OBT) has been proposed as a reliable alternative indirect method for measuring gastric emptying 
of solids.9-11  
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Currently, there is no treatment with established efficacy for FD. In the primary care setting, the 
first-line therapeutic approach is often represented by antacids, proton pump inhibitors (PPI) and/or 
prokinetic drugs, such as domperidone, according to predominant symptom.1 Antidepressant, anxiolytic 
and other prokinetic drugs should be taken into account in patients non-responders to first-line 
treatment. 
The aim of this study was to investigate, in a specialistic setting, the association between FD 
symptoms and OBT parameters before and after treatment with buspirone, amitriptyline or clebopride, 
in patients unresponsive to first-line treatment.  
 
METHODS 
Patients  
The study was conducted at the third-level Outpatient Clinic of Gastroenterology, Molinette and 
San Giovanni Antica Sede Hospital, Turin, Italy. The flow chart of the study is depicted in Figure 1. 
From a total of 870 patients with upper abdominal complaints, who underwent OBT for gastric 
emptying measurement, between January 2007 and December 2014, we retrospectively enrolled 59 
patients with FD diagnosed according to Rome III criteria and unresponsive to first-line therapy with 
PPI and/or domperidone.3 To meet the criteria for the definition of FD, patients had to have undergone 
upper gastrointestinal endoscopy. All included subjects had repeated OBT assessment after 12 weeks of 
second-line treatment. Seven patients reported a previous history of H. pylori infection, with therapy 
taken more than 6 months before OBT assessment, and eradication confirmed by urea breath test. The 
remaining patients had negativity ab initio for this infection. Data regarding dyspeptic symptoms 
(bothersome postprandial fullness, early satiation, epigastric pain and epigastric burning) were 
collected before and after treatment, and scored according to severity (0 = absent, 1 = mild, when the 
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symptom could not be ignored, but did not influence daily activities, 2 = severe, when the symptom 
influenced daily activities).13  
Overall, 32 patients were orally treated for 12 weeks with buspirone 10 mg twice daily, 16 
patients with amitriptyline 4.5 mg twice daily for the first 2 days followed by 7.5 mg twice daily for the 
remaining treatment period, and 11 patients with clebopride 5 mg twice daily before meals for the 
entire period. 
The study protocol was conformed to the Declaration of Helsinki guidelines. Data were 
managed with respect of patients’ privacy. All patients gave their written informed consent prior to 
treatment. 
 
 13C-octanoic acid breath test  
Gastric emptying rate was determined by OBT. All patients were fasted for 12 hours prior to 
undergoing breath test. Weight and height were assessed, and 2 basal breath samples were collected 
before meal. The test meal consisted in a muffin (EXPIROGer®, SOFAR, Italy) with a total caloric 
value of 378 kcal (57 g carbohydrate, 14 g fat, 6 g protein and 100 mg of 13C-Octanoic acid without 
gluten, glucose and lactose) and 150 mL of natural water.9, 11 Afterwards, breath samples were 
collected in 10 mL plastic tubes every 15 minutes up to a 4-hours period. The ratio of 13CO to 12CO 
was measured in each breath sample by isotope ratio mass-spectrometer (QuinTron Instrument 
Company, USA).14 The parameters calculated were gastric half-emptying time (t1/2), defined as the 
time needed by the stomach to metabolize and excrete the half of 13C-labeled substrate, gastric lag 
phase (tlag), defined as the required time to reach the maximum emptying peak of the 13C-labeled 
substrate, and gastric emptying coefficient (GEC), an index that accounts for the rates of both 
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appearance and disappearance of the label in breath.15, 16 According to the supplier’s instructions, 
delayed gastric emptying was defined as t1/2 of more than 120 minutes. 
 
Statistical Analysis 
Continuous variables were expressed as median and 95% confidence interval (CI) of the 
median. Test for normal distribution was performed by D'Agostino-Pearson normality test. Kruskal-
Wallis test and chi-squared test were performed to compare basal continuous and categorical variables, 
respectively. Pearson’s correlation coefficient (r) was used to measure the degree of association 
between two continuous variables. Wilcoxon test and Kendall's coefficient of concordance were used 
to compare paired continuous and categorical variables before and after treatment, respectively.  
For all analyses, a p<0.05 was considered significant. All statistical analyses were performed by 
SPSS software version 22.0 (IBM SPSS Statistics for Windows, Chicago, IL). 
 
RESULTS 
Basal demographical, clinical data and OBT parameters of the 59 enrolled patients are reported 
in Table I. Median age was 49.9 years and the majority of patients were females (79.7%). Age 
distribution was significantly different according to treatment regimen (p=0.034). In particular, patients 
treated with buspirone were older than those treated with clebopride (54.1 years vs. 37.2 years, 
p=0.011). Age was positively correlated with early satiation severity (r=0.2633, 95%CI: 0.0077 - 
0.4866; p=0.044) and with tlag values (r=0.2680, 95% CI: 0.0055 - 0.4959; p=0.046) and negatively 
correlated with post-prandial fullness (r=-0.2809, 95% CI: -0.5009 - -0.0267; p=0.031). In addition, a 
trend towards a correlation between age and t1/2 (r=0.2458, 95% CI: -0.0110 - 0.4722; p=0.061) was 
observed. Body mass index (BMI) was neither associated with clinical and demographical data nor 
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with OBT parameters. No difference was found in basal OBT parameters according to treatment 
subgroups (t1/2, p=0.438; tlag, p=0.260; and GEC, p=0.416). Symptoms severity distribution was 
significantly different, according to treatment regimen, for early satiation (p=0.006) and a trend could 
be denoted for epigastric pain (p=0.073), whereas no differences were found for post-prandial fullness 
and for epigastric burning. In particular, 16 out of 20 patients with severe early satiation, and 7 out of 9 
with mild early satiation, respectively, were treated with buspirone. In addition, early satiation severity 
was positively correlated with t1/2 values (r=0.3789, 95% CI: 0.1360 - 0.5788; p=0.003) and tlag values 
(r=0.3371, 95% CI: 0.0815 - 0.5512; p=0.011) and negatively correlated with GEC (r= -0.3231, 95% 
CI: -0.5401 - -0.0658; p=0.015).  
All patients underwent a second OBT assessment after 90 ± 15 days of treatment. Overall, a 
significant reduction of t1/2 measurement associated to a significant improvement of post-prandial 
fullness and early satiation severity were observed (p=0.009, p=0.005 and p<0.001, respectively) 
(Table II and Table III). According to treatment regimen, patients that underwent buspirone-based 
therapy obtained a significant reduction in t1/2 values (p=0.005) and a significant amelioration in early 
satiation (p=0.001). In addition, a trend toward tlag and GEC amelioration values was found (p=0.085 
and p=0.060, respectively). Patients treated with amitriptyline experienced a significant improvement 
in post-prandial fullness (p=0.046), whereas no significant variation was reported in patients under 
clebopride therapy in OBT parameters and in symptoms severity. 
Three out of 59 enrolled patients reported mild side effects: one under buspirone treatment 
experienced dizziness whereas other two treated with amitriptyline reported dysgeusia and asthenia, 
respectively. Nevertheless, none of them stopped treatment. 
 
DISCUSSION 
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This retrospective study, conducted in the real world, explored the effect of buspirone, 
amitriptyline and clebopride treatment on symptoms severity and OBT parameters in patients with FD 
diagnosis.  
In agreement with previous observations,17 we found a weak correlation between older age and 
worse OBT parameters, particularly with tlag (r=0.2680; p=0.046). In addition, age was directly 
associated with early satiety severity, and had an inverse relationship with the prolonged fullness. It has 
been hypothesized that older patients have a slow gastric motility due to the decreased number of Cajal 
cells, a nervous-like cell type involved in electrical rhythmicity generation in smooth muscles.18  
In contrast to other data, BMI was neither correlated with symptoms severity nor with OBT 
parameters.19 However, our cohort included normal-weight patients (BMI was in the normal range of 
18.0-24.9 Kg/cm2), therefore we could not assessed the association between symptoms and OBT 
parameters in over-weight or obese subjects.   
Currently, available data regarding correlation between symptoms severity and OBT parameters 
are controversial.20 In the present study, we found a significant association between early satiation and 
all OBT parameters, suggesting that alterations in gastric motility may underlie FD manifestations.  
After 3 months of therapy, we found a significant improvement of post-prandial fullness 
(p=0.005) and early satiation severity (p<0.001) together with a significant t1/2 reduction (p=0.009). In 
particular, buspirone led to early satiation and t1/2 improvement (p=0.001 and p=0.005, respectively), 
and amitriptyline in post-prandial fullness amelioration (p=0.046), whereas no significant variation was 
observed in patients treated with clebopride. As reported by Tack et al, in a prospective randomized 
trial, buspirone may be most beneficial for patients with meal-related dyspepsia without affecting 
symptoms characteristics of epigastric pain syndrome. However, the authors did not observe any 
concomitant significant change in solid emptying time assessed by breath test.21 In contrast to our 
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results, Talley et al, in a recent multicenter trial, found that amitriptyline appeared to induce benefit 
mainly in FD patients with ulcer-like pain.22 Probably, the low number of patients enrolled in our study 
may result in different findings. Regarding clebopride, the absence of clinical relief emphasized by no 
variation in OBT parameters could be explained by the feature of included patients already 
unresponsive to first-line therapy with domperidone. Hence, the use of another prokinetic drug, as 
rescue treatment, did not led to any symptom improvement.  
The main limitation of our study is represented by its retrospective design. All patients were 
recruited between 2007 and 2014, thus FD diagnosis was set according to Rome III criteria. However, 
in the setting of FD, only minor changes have been introduced following Rome IV classification. 
Therefore, we think that patients’ classification can be considered valid. In addition, patients’ 
enrolment did not allow us to evaluate symptoms severity by validated scores, such as dyspepsia 
severity score or visual analogue scale. To clarify the allocation of patients to treatment, it should be 
highlighted that according to literature, our choice is usually to plan a rescue therapy on the basis of the 
prevalent symptom,3 using buspirone in case of meal-related symptoms and amitriptyline when an 
associated psychological disorder (anxiety, depression or both) can be recognized. Finally, clebopride 
is used in absence of these conditions or in case of patient’s refusal to other treatments. On the other 
hand, the low number of patient treated with amitriptyline and clebopride may have underpowered the 
results obtained in our study. In fact, patients treated with amitriptyline experienced an improvement 
for both symptoms severity and OBT parameters without reaching a statistical significance. However, 
to our knowledge, this is the largest cohort of patients with FD treated with buspirone that underwent 
OBT before and after treatment. Moreover, this population reflects what happens in real clinical 
practice. 
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An unsolved issue remains the search and the treatment for H. pylori infection in FD patients. 
Although worldwide data are heterogeneous, both in terms of prevalence and post-eradication 
benefit,23-25 the European guidelines state that bacterial cure produced long-term benefits in one of 12 
patients with H. pylori infection and FD, and that this is better than any other treatment.26 Considering 
that the choice of the more appropriate treatment should be based on local antibiotic usage, documented 
antibiotic resistance and outcome data,27 before starting a long-term treatment, as those reported in our 
study, the search for the bacterium could be performed. On the other hand, it has been reported that 
there is no relationship between H. pylori infection and gastric emptying in patients with FD.28 
In conclusion, we found that FD was associated with gastric motility abnormalities detectable 
by OBT. In addition, there was a relationship between symptoms amelioration and the decrease in 
gastric solid emptying time. Patients non-responders to first-line therapy with PPI and/or domperidone, 
reporting meal-related discomfort, may benefit from buspirone or amitriptyline-based therapy with no 
relevant side effects.  
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Table I. Basal characteristics of the 59 enrolled patients 
 Total Buspirone Amitriptyline Clebopride P 
Patient number 59 32 16 11  
Age, years 49.9 (44.7-54.6) 54.1 (45.4-60.7) 50.6 (38.0-60.4) 37.2 (26.3-53.5) 0.034 
Gender, M/F 12/47 7/25 2/14 2/9 0.613 
BMI, Kg/cm2 22.5 (21.6-23.2) 22.5 (21.5-24.7) 23.1 (20.7-24.1) 21.6 (20.5-23.6) 0.652 
OBT 
• t1/2, min  
• tlag, min 
• GEC 
 
224 (203-338) 
113 (94-136) 
2.5 (2.4-2.6) 
 
213 (184-327) 
94 (81-115) 
2.6 (2.4-2.7) 
 
261 (146-422) 
135 (81-186) 
2.5 (2.3-2.7) 
 
350 (187-569) 
138 (79-321) 
2.5 (2.1-2.5) 
 
0.438 
0.260 
0.416 
Symptoms, absent/mild/severe 
• Postprandial fullness 
• Early satiation 
 Epigastric pain 
 Epigastric burning 
 
32/16/11 
30/9/20 
42/10/7 
38/15/6 
 
21/8/3 
9/7/16 
27/2/3 
19/7/6 
 
7/5/4 
13/1/2 
8/6/2 
11/5/0 
 
4/3/4 
8/1/2 
7/2/2 
8/3/0 
 
0.234 
0.006 
0.073 
0.219 
 
p values were calculated by Kruskal-Wallis test or by chi-squared test for continuous or categorical 
variables, respectively.  
Abbreviations: F, female; GEC, gastric emptying coefficient; M, male; OBT, 13C-octanoic acid breath 
test. 
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Table II. Comparison of symptoms severity before (T0) and after therapy (T1) with buspirone, 
amitriptyline and clebopride 
  T0 T1 p 
Total Symptoms, absent/mild/severe 
• Postprandial fullness 
• Early satiation 
• Epigastric pain 
• Epigastric burning 
 
32/16/11 
30/9/20 
42/10/7 
38/15/6 
 
35/23/1 
34/22/3 
44/13/2 
39/18/2 
 
0.005 
< 0.001 
0.052 
0.248 
Buspirone Symptoms, absent/mild/severe 
• Postprandial fullness 
• Early satiation 
• Epigastric pain 
• Epigastric burning 
 
21/8/3 
9/7/16 
27/2/3 
19/7/6 
 
22/10/0 
12/18/2 
28/2/2 
19/11/2 
 
0.157 
0.001 
0.414 
0.206 
Amitriptyline Symptoms, absent/mild/severe 
• Postprandial fullness 
• Early satiation 
• Epigastric pain 
• Epigastric burning 
 
7/5/4 
13/1/2 
8/6/2 
11/5/0 
 
9/6/1 
13/3/0 
9/7/0 
11/5/0 
 
0.046 
0.157 
0.180 
1.000 
Clebopride Symptoms, absent/mild/severe 
• Postprandial fullness 
• Early satiation 
• Epigastric pain 
• Epigastric burning 
 
4/3/4 
8/1/2 
7/2/2 
8/3/0 
 
4/7/0 
9/1/1 
7/4/0 
8/3/0 
 
0.102 
0.157 
0.157 
1.000 
 
p values were calculated by Kendall test. 
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Table III. Comparison of OBT parameters before (T0) and after therapy (T1) with buspirone, 
amitriptyline and clebopride 
  T0 T1 p 
Total OBT 
• t1/2, min 
• tlag, min 
• GEC 
 
224 (203-338) 
113 (94-137) 
2.5 (2.4-2.6) 
 
154 (130-186) 
81 (60-121) 
2.5 (2.4-2.7) 
 
0.009 
0.114 
0.307 
Buspirone OBT 
• t1/2, min 
• tlag, min 
• GEC 
 
213 (184-327) 
94 (81-115) 
2.6 (2.4-2.7) 
 
136 (123-167) 
62 (42-101) 
2.7 (2.5-2.8) 
 
0.005 
0.085 
0.060 
Amitriptyline OBT 
• t1/2, min 
• tlag, min 
• GEC 
 
261 (146-422) 
135 (81-186) 
2.5 (2.3-2.7) 
 
160 (126-252) 
88 (59-141) 
2.4 (2.4-2.7) 
 
0.121 
0.217 
0.910 
Clebopride OBT 
• t1/2, min 
• tlag, min 
• GEC 
 
350 (187-569) 
138 (79-321) 
2.5 (2.1-2.5) 
 
249 (105-867) 
129 (51-461) 
2.2 (1.8-2.7) 
 
0.831 
0.492 
0.359 
 
p values were calculated by Wilcoxon test.  
Abbreviations: GEC, gastric emptying coefficient; OBT, 13C-octanoic acid breath test. 
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Figure 1. Flow chart of the study 
 
Abbreviations: FD, functional dyspepsia; OBT, 13C-octanoic acid breath test. 
 
